Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
05 Octobre 2023 - 2:00PM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that members of management will participate in a
fireside chat at the Jefferies Biotech CNS/Neuro Summit on
Thursday, October 12 at 9:00 a.m. ET.
A live webcast of the fireside chat, as well as an archived
recording, will be available on Avadel’s Investor Relations
website, investors.avadel.com, for 90 days following the
conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical
company focused on transforming medicines to transform lives. Our
approach includes applying innovative solutions to the development
of medications that address the challenges patients face with
current treatment options. Avadel’s commercial product, LUMRYZ™,
was approved by the U.S. Food & Drug Administration (FDA) as
the first and only once-at-bedtime oxybate for the treatment of
cataplexy or excessive daytime sleepiness (EDS) in adults with
narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Lesley StanleyReal
Chemistrylestanley@realchemistry.com(609) 273-3162
Avadel Pharmaceuticals (NASDAQ:AVDL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024